1:1
Analysis of registry data offers critical insights into the progression of seizures and speech development in patients with Dravet syndrome.

This study utilises patient registry data to track the natural history of Dravet syndrome, focusing on how seizure frequency and speech abilities evolve over time. The findings provide a baseline for evaluating the efficacy of future therapeutic interventions.

Year of publication

2025

Source

Epilepsy & Behavior

Link to cite

Acces to Link >

Author

elporte M, Verbeeck J, Brambilla I, Zimmermann G, Molenberghs G, Nabbout R, et al.

You might also be interested in

The two-day event will focus on translating research and policy initiatives into tangible benefits for Rare Disease patients through better prevention, diagnosis, and treatment.
13 January – 10 February 2026 | Online webinar series to advance best practices in clinical trial design for rare and ultra rare diseases.
EMA seeks stakeholder input on new reflection paper to reduce and replace non‑human primate use in medicines safety testing through 3Rs approaches.
Outside traditional drug development pathways, clinicians and scientists face the challenge of systematically evaluating whether individual patients with severe ultrarare diseases might be eligible for and potentially benefit from individualized mutation-specific RNA therapies.